Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2

[1]  M. Koopmans,et al.  Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial , 2023, The Lancet Infectious Diseases.

[2]  Reed J. D. Sorensen,et al.  Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis , 2023, The Lancet.

[3]  Stephen J. Thomas,et al.  Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years , 2023, The New England journal of medicine.

[4]  E. Lau,et al.  Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population , 2023, Nature Medicine.

[5]  D. Montefiori,et al.  A Bivalent Omicron-Containing Booster Vaccine against Covid-19 , 2022, The New England journal of medicine.

[6]  D. Barouch,et al.  Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 , 2022, The New England journal of medicine.

[7]  Reed J. D. Sorensen,et al.  Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis , 2022, The Lancet.

[8]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[9]  Diana Duong.  Alpha, Beta, Delta, Gamma: What’s important to know about SARS-CoV-2 variants of concern? , 2021, Canadian Medical Association Journal.

[10]  R. Guiomar,et al.  Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution , 2021, bioRxiv.